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Background: Multiple anti-PD-L1/PD-1 checkpoint monoclonal antibodies (MAb) have shown clear evidence of clinical
benefit. All except one have been designed or engineered to omit the possibility to mediate antibody-dependent
cell-mediated cytotoxicity (ADCC) as a second potential mode of anti-tumor activity; the reason for this is the
concern of lysis of PD-L1 positive immune cells. Avelumab is a fully human IgG1 MAb which has been shown
in prior in vitro studies to mediate ADCC versus a range of human tumor cells, and clinical studies have demonstrated
anti-tumor activity versus a range of human cancers. This study was designed to investigate the effect on immune cell
subsets in the peripheral blood of cancer patients prior to and following multiple administrations of avelumab.
Methods: One hundred twenty-three distinct immune cell subsets in the peripheral blood of cancer patients (n = 28)
in a phase I trial were analyzed by flow cytometry prior to and following one, three, and nine cycles of avelumab.
Changes in soluble (s) CD27 and sCD40L in plasma were also evaluated. In vitro studies were also performed to
determine if avelumab would mediate ADCC of PBMC.
Results: No statistically significant changes in any of the 123 immune cell subsets analyzedwere observed at any dose level, or
number of doses, of avelumab. Increases in the ratio of sCD27:sCD40Lwere observed, suggesting potential immune activation.
Controlled in vitro studies also showed lysis of tumor cells by avelumab versus no lysis of PBMC from five donors.
Conclusions: These studies demonstrate the lack of any significant effect onmultiple immune cell subsets, even those
expressing PD-L1, followingmultiple cycles of avelumab. These results complement prior studies showing anti-tumor effects of
avelumab and comparable levels of adverse events with avelumab versus other anti-PD-1/PD-L1MAbs. These studies provide
the rationale to further exploit the potential ADCCmechanism of action of avelumab as well as other human IgG1 checkpoint
inhibitors.
Trial registration: ClinicalTrials.gov identifier: NCT01772004 (first received: 1/14/13; start date: January 2013) and NCT00001846
(first received date: 11/3/99; start date: August 1999).
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Immune checkpoint inhibition employing monoclonal
antibodies (MAbs) directed against programmed cell
death protein 1 (PD-1) or programmed cell death
protein-1 ligand (PD-L1) has been a major advance in
the management of selected patients in several tumor
types and stages (see [1, 2] for recent reviews). The gen-
eral concept is that the interaction of PD-1 on immune
cells with PD-L1 on tumor cells can lead to immune cell
anergy and thus the lack of anti-tumor activity; the use
of either anti-PD-1 or PD-L1 MAbs is designed to block
this interaction leading to tumor cell lysis. The use of a
human anti-PD-L1 MAb of the IgG1 isotype could
potentially add another mode of anti-tumor activity.
Human IgG1 MAbs have been shown to be capable of
mediating antibody-dependent cell-mediated cytotoxicity
(ADCC) via the interaction of the IgG1 Fc region with
its ligand on human natural killer (NK) cells. One cau-
tion in the use of this approach is that several human
immune cell populations also express PD-L1, and could
thus potentially also be susceptible to ADCC-mediated
lysis. It is for this reason that, with one exception, all of
the anti-PD-L1 MAbs in clinical studies to date were
constructed as either an IgG4 isotype that cannot
mediate ADCC, or an IgG1 MAb engineered to be
devoid of ADCC activity; the one exception is the devel-
opment of the human IgG1 anti-PD-L1 MAb avelumab
(MSB0010718C). We have previously shown that avelu-
mab can mediate ADCC in vitro using as targets a range
of human tumor cell lines that express PD-L1, and that
this lysis can be blocked using an anti-CD16 antibody to
inhibit the interaction of CD16 on NK cells with the IgG1
Fc receptor on avelumab [3–5]. We have also shown that
avelumab can mediate tumor lysis in vivo using a murine
tumor model [6]. A recent study also showed that the
addition of avelumab to an in vitro assay leads to en-
hanced antigen-specific T-cell activation [7]. A Phase I
dose escalation trial (NCT01772004) and use of avelumab
in multiple expansion cohorts have shown evidence of
clinical benefit of avelumab in patients with thymoma,
mesothelioma, non-small cell lung cancer (NSCLC), ovar-
ian, gastric and urothelial cancer, among others [8–13]. A
recent phase II study [14] also demonstrated clinical
activity of avelumab in Merkel cell carcinoma. In the
dose escalation trial, there were no dose-limiting toxic-
ities (DLT) in dose levels 1, 2, and 3 (1, 3, and 10 mg/kg)
and one DLT on dose level 4 (20 mg/kg) concurrent with
an anti-tumor response [[11]; Heery, et al. First-in-human
phase 1 dose-escalation trial of avelumab. Lancet Oncol.,
In press]. At the time of writing, multiple Phase III trials
of avelumab are ongoing in patients with a range of tumor
types and stages.
As mentioned above, one of the concerns in the use of
an IgG1 anti-PD-L1 MAb is the potential effect on PD-L1 expressing immune cells. We have recently described
a methodology in which 123 different immune cell sub-
sets can be analyzed by flow cytometry using one tube
of blood (approximately 107 peripheral blood mono-
nuclear cells (PBMC)). We have previously reported the
relative distributions of these 123 classic and refined
subsets in healthy donors vs. metastatic cancer patients
[15]. In this study, we interrogated the effect of adminis-
tration of different doses of avelumab on multiple
peripheral immune cell subsets; the 123 immune cell
subsets were analyzed prior to and following one, three
and nine cycles of avelumab every 2 weeks. The effect of
avelumab administration on changes in soluble CD27
(sCD27) and soluble CD40 ligand (sCD40L) in plasma
was also evaluated. In controlled studies, the ability of
avelumab to mediate ADCC of tumor cells vs. peripheral
immune cells was conducted using NK cells as effectors
from five different healthy donors and three cancer pa-
tients. Potential strategies to exploit the ADCC potential
of avelumab are also discussed.
Methods
Cancer patients and healthy donors
Flow cytometry analysis was performed on PBMC of
cancer patients who were enrolled in a first-in-human,
open-label, dose-escalation and expansion Phase 1 clin-
ical trial (NCT01772004). The National Cancer Insti-
tute Institutional Review Board approved the trial
procedures and informed consent was obtained in ac-
cordance with the Declaration of Helsinki. Metastatic
cancer patients with solid tumors were treated with 1,
3, 10 or 20 mg/kg of avelumab every 2 weeks [Heery, et
al. First-in-human phase 1 dose-escalation trial of ave-
lumab. Lancet Oncol., In press]. Based on PBMC avail-
ability, the flow cytometry analysis included 28 patients
with 12 different types of solid tumors: adrenocortical
(n = 2), breast (n = 3), chordoma (n = 1), gastrointestinal
(GI) (n = 7), lung (n = 1), mesothelioma (n = 3), neuro-
endocrine (n = 1), ovarian (n = 1), pancreatic (n = 4),
prostate (n = 1), renal cell (n = 3) and spindle cell (n = 1)
cancer. Patients received 1 or 3 mg/kg (n = 11), 10 mg/
kg (n = 8), or 20 mg/kg (n = 9) of avelumab. Based on
plasma availability, the soluble factor analysis included
39 patients receiving 1 or 3 mg/kg (n = 15), 10 mg/kg
(n = 13), or 20 mg/kg (n = 11) of avelumab. PBMC for
in vitro ADCC assays were obtained from five healthy
donors from the NIH Clinical Center Blood Bank
(NCT00001846) and three NSCLC patients enrolled in
a previously described trial before the initiation of
therapy [16]. PBMC for the antibody competition assay
were obtained from a patient with metastatic castra-
tion resistant prostate cancer (mCRPC) enrolled in a
previously described trial before the initiation of
therapy [17].
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Multicolor flow cytometry was performed on frozen
PBMC as previously described [15]. One vial of PBMC
containing 107 cells was thawed per cancer patient prior
to therapy (n = 28) and 2 weeks after patients were
administered the first cycle (PBMC tested on ~ day 15, n
= 19), third cycle (PBMC tested on ~ day 43, n = 14), and
ninth cycle (PBMC tested on ~ day 127, n = 16) of avelu-
mab. PBMC were counted and assessed for cell viability
with trypan blue exclusion. Median cell viability was
92% (89–95% interquartile range), and less than 5% of
PBMC samples assayed from the trial (4/81) hadTable 1 Complete list of 123 peripheral immune cell subsets analyz










o PD-L1+ ICOS+ CD4
o PD-1+ ICOS+ CD4
• Total naïve (CCR7+CD45RA+) CD4
o PD-L1+ naïve CD4
o PD-1+ naïve CD4
o CTLA-4+ naïve CD4
o Tim-3+ naïve CD4
• Total central memory (CCR7+ CD45RA-) CD4
o PD-L1+ CM CD4
o PD-1+ CM CD4
o CTLA-4+ CM CD4
o Tim-3+ CM CD4
• Total effector memory (CCR7- CD45RA-) CD4
o PD-L1+ EM CD4
o PD-1+ EM CD4
o CTLA-4+ EM CD4
o Tim-3+ EM CD4
• Total EMRA (CCR7-CD45RA+) CD4
o PD-L1+ EMRA CD4
o PD-1+ EMRA CD4
o CTLA-4+ EMRA CD4
o Tim-3+ EMRA CD4









• Total naïve (CCR7+CD45RA+) CD8
o PD-L1+ naïve CD8
o PD-1+ naïve CD8
o CTLA-4+ naïve CD8
o Tim-3+ naïve CD8
• Total central memory
o PD-L1+ CM CD8
o PD-1+ CM CD8
o CTLA-4+ CM CD8
o Tim-3+ CM CD8
• Total effector memory
o PD-L1+ EM CD8
o PD-1+ EM CD8
o CTLA-4+ EM CD8
o Tim-3+ EM CD8
• Total EMRA (CCR7-CD4
o PD-L1+ EMRA CD8
o PD-1+ EMRA CD8
o CTLA-4+ EMRA CD8








4. Total B cells
• PD-L1+ B cells
• PD-1+ B cells
• CTLA-4+ B cells





• Total mature (CD16+ C
o PD-L1+ mature NK
o PD-1+ mature NK
o Tim-3+ mature NK
• Total functional interme
o PD-L1+ functional i
o PD-1+ functional in
o Tim-3+ functional in
Nine classic subsets were identified as well as 114 refined subsets relating to matur
BATF basic leucine zipper transcription factor ATF-like, cDC conventional dendritic c
EM effector memory, EMRA terminally differentiated effector memory, EOMES eome
neg MDSC lineage negative MDSC, MDSC myeloid derived suppressor cell, mMDSC m
death protein 1, PD-L1 programmed cell death ligand-1, Tbet T box expressed in T c
Tregs regulatory T cellsviabilities <80%. Samples with viability <80% were anno-
tated in the analysis to ensure that low viability did not
impact the ability to detect PD-L1. PBMC were stained
with five different antibody panels (Additional file 1:
Table S1). These panels identified markers involved in
PD-1 signaling (panel 1), CD4+ and CD8+ T cells, and B
cells (panel 2), regulatory T cells (Tregs) (panel 3), NK
cells, NK-T cells, conventional dendritic cells (cDC)
and plasmacytoid DC (pDC) (panel 4), and myeloid de-
rived suppressor cells (MDSC) (panel 5). A total of 123
peripheral immune cell subsets were analyzed (Table 1









• Total immature (CD16- CD56br) NK
o PD-L1+ immature NK
o PD-1+ immature NK
o Tim-3+ immature NK
• Total unconventional (CD16- CD56dim) NK
o PD-L1+ unconventional NK
o PD-1+ unconventional NK



























• Total lineage negative (CD14- CD15-) MDSC
o PD-L1+ lin neg MDSC
o PD-1+ lin neg MDSC
o CD16+ lin neg MDSC
ation and function within the classic subsets (Lepone et al., ref. [15])
ells, CM central memory, CTLA-4 cytotoxic T lymphocyte-associated protein-4,
sodermin, gMDSC granulocytic MDSC; ICOS inducible T cell co-stimulator, lin
onocytic MDSC, NK natural killer, pDC plasmacytoid DC, PD-1 programmed cell
ells, TCR T cell receptor, Tim-3 T cell immunoglobulin and mucin domain-3,
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refined subsets related to maturation and function. Fol-
lowing staining, samples were acquired on a BD LSRII
cytometer (BD Biosciences, San Jose, CA) equipped
with four lasers (UV, violet, blue, and red). The cyt-
ometer is serviced by BD technicians under a service
contract, and is calibrated daily before use with cyt-
ometer setup and tracking beads to ensure quality
performance. The laser configuration and filter sets
are shown in Additional file 2: Figure S1. Voltages
were adjusted to allow both negative and positive signals
to be visualized and to minimize spectral overlap be-
tween channels. FCS files were exported and analyzed
using FlowJo v9.7 for Macintosh (Treestar, Ashland,
OR) using the outlined gating strategy (Fig. 1), with
non-viable cells excluded and negative gates set based
on fluorescence minus one controls. Compensation was
performed in FlowJo using beads (BD Biosciences) that
were single stained with each of the antibodies in the 5
panels. The frequency of all subsets was calculated as a
percentage of PBMC to help eliminate the bias that
could occur in the smaller populations with fluctua-
tions in leukocyte subpopulations. The methodology
used to analyze the flow cytometry data in the current
study is identical to that of Lepone et al. [15].
Measurement of soluble factors in plasma
Plasma levels of sCD27 and sCD40L were determined
using human sCD27 and sCD40L Instant ELISA kits
(eBioscience, San Diego, CA). One vial of frozen plasma
per cancer patient was assayed prior to therapy and fol-
lowing one cycle (~day 15, n = 39) and three cycles
(~day 43, n = 33) of avelumab.
In vitro ADCC assay
NK effectors were isolated from PBMC using the Hu-
man NK Cell Isolation (negative selection) Kit (Miltenyi
Biotech, San Diego CA) following the manufacturer’s
protocol, resulting in >90% purity. NK cells were allowed
to rest overnight in RPMI 1640 medium (Corning Cell-
gro, Manassas, VA) supplemented with 10% human AB
serum (Omega Scientific, Tarzana, CA), 100 U/mL peni-
cillin, 100 μg/mL streptomycin and 2 mM L-glutamine
(Corning Cellgro, Corning, NY).
Human lung NCI-H441 [H441] (ATCC® HTB-174™)
and NCI-H460 [H460] (ATCC® HTB-177™) carcinoma
cells as well as PBMC from healthy donors and cancer
patients were used as targets with purified NK cells as
effectors in the presence of avelumab or isotype control
antibody at a concentration of 1 ng/mL. Prior to use as
targets in the ADCC assay, PBMC from cancer patients
were sorted to enrich for PD-L1+ and PD-L1- cells;
PBMC were rested overnight, stained with PD-L1-PE-Cy7
(clone MIH-1, BD Biosciences) followed by Anti-Cy7microbeads (Miltenyi Biotech) and PD-L1+ and PD-L1-
fractions isolated by magnetic selection. To determine the
ADCC activity, a 4-h 111In-release assay was performed,
as previously described [3]. Effector cell-to-target cell
(E:T) were used at ratios of 25:1, 12.5:1 and 6.25:1 for
assays with healthy donor NK, and 25:1 for experiments
with cancer patient NK. Spontaneous release was deter-
mined by incubation of target cells with medium alone,
and complete lysis by incubation with 0.05% Triton X-100.
Specific ADCC lysis was determined using the following
equation: percent lysis = (experimental - spontaneous)/
(complete - spontaneous) x 100.
Antibody competition assay
PBMC from a cancer patient with mCRPC were rested for
48 h and then pre-incubated for 30 min with avelumab or
IgG1 isotype control at 0.2, 2, and 20 μg/mL, washed and
then stained with multiparametric flow cytometry, as de-
scribed above, to detect PD-L1 (with the MIH-1 clone)
within the various immune cell types. PBMC that were
not pre-incubated with avelumab or the isotype control
also served as controls. The frequency of PD-L1 within
each of the classic immune cell types was determined both
as a percentage of parent and total PBMC.
FcγRIIIa (CD16) genotyping
To examine the polymorphism of CD16 (valine (V) ver-
sus phenylalanine (F) substitution at amino acid position
158), DNA was extracted from PBMC of healthy donors
and cancer patients receiving avelumab using the
QIAamp DNA Blood Mini kit (Qiagen, Valencia, CA)
and stored at −80 °C until use. The FcγRIIIa (CD16)
genotype was determined by performing allele-specific
droplet digital polymerase chain reaction (ddPCR) using
the TaqMan array for CD16 (rs396991; Life Technolo-
gies, Carlsbad, CA) [18]. A master reaction mix was pre-
pared, and 1 μL of DNA was added. The PCR reaction
was performed as previously described [3].
Statistical analyses
Statistical analyses were performed using GraphPad
Prism 6 (GraphPad Software, La Jolla, CA), and p-values
were calculated using the Wilcoxon matched-pairs
signed rank test. For the flow cytometry analysis, due to
the large number of tests performed, p-values were ad-
justed using Holm’s method (step-down Bonferroni), as
previously described [15, 19]. The adjustment was made
for the number of subsets with a frequency above 0.01%
of PBMC (n = 9 for classic subsets, n = 29 for subsets in
CD4+ T cells, n = 25 for CD8+ T cells, n = 5 for Tregs, n
= 14 for NK cells, n = 3 for NK-T cells, n = 4 for B cells,
n = 2 for cDCs, n = 3 for pDCs, n = 15 for MDSC). Sub-
sets with a potentially biologically relevant change were
defined as subsets with a Holm adjusted p < 0.05,
Fig. 1 Gating strategy to identity 123 peripheral immune cell subsets. Five immune flow cytometry panels using PBMC from a cancer patient
following nine cycles of avelumab were used. Classic immune cell types included CD4+ T cells, CD8+ T cells, Tregs, B cells, natural killer (NK) and
NK-T cells (panel a), and conventional dendritic cells (cDCs), plasmacytoid DCs (pDCs) and myeloid derived suppressor cells (MDSCs) (panel b)
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Table 2 Baseline expression of PD-L1




PD-L1+ CD4 0.08 0.25
PD-L1+ ICOS+ CD4 0.05 0.81
PD-L1+ naïve CD4 0.01 0.26
PD-L1+ CM CD4 0.02 0.28
PD-L1+ EM CD4 0.06 0.31
PD-L1+ EMRA CD4 0.01 0.35
PD-L1+ CD8 0.04 0.29
PD-L1+ naïve CD8 <0.01 0.40
PD-L1+ CM CD8 <0.01 0.41
PD-L1+ EM CD8 0.02 0.26
PD-L1+ EMRA CD8 0.01 0.30
PD-L1+ Tregs <0.01 0.38
PD-L1+ NK 0.06 1.03
PD-L1+ mature NK 0.04 0.97
PD-L1+ functional intermediate NK <0.01 0.31
PD-L1+ immature NK <0.01 0.66
PD-L1+ unconventional NK 0.02 5.58
PD-L1+ NK-T 0.03 1.34
PD-L1+ B cells 0.88 11.22
PD-L1+ cDC 0.02 7.12
PD-L1+ pDC 0.02 9.85
PD-L1+ MDSC 0.71 16.54
PD-L1+ mMDSC 0.10 4.81
PD-L1+ gMDSC 0.26 35.77
PD-L1+ lin neg MDSC 0.17 18.75
In 28 patients prior to avelumab therapy, expression of PD-L1 was measured
by flow cytometry in 9 classic subsets and 16 refined subsets as both percentage
of total PBMC and of parental cell type
cDC conventional dendritic cells, CM central memory, EM effector memory,
EMRA terminally differentiated effector memory, gMDSC granulocytic MDSC,
ICOS inducible T cell co-stimulator, lin neg MDSCs lineage negative MDSCs,
MDSC myeloid derived suppressor cell, mMDSC monocytic MDSC, NK natural
killer, pDC plasmacytoid DC, PD-L1 programmed cell death ligand-1, Tregs
regulatory T cells
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pre- vs. post-therapy >0.01% of PBMC, and a frequency
>0.01% of PBMC. Trends were defined as subsets with an
unadjusted p < 0.05, along with the additional criteria used
to define changes.
Results
To interrogate any potential effects of the anti-PD-L1
monoclonal (avelumab) on immune cells in cancer pa-
tients, we employed five panels of antibodies in flow cy-
tometry analyses to define 123 different immune cell
subsets. The antibody panels used are shown in Additional
file 1: Table S1. The complete list of subsets analyzed is
shown in Table 1. Additional file 1: Table S2 shows the
“classic” immune cell types (CD4+ and CD8+ T cells, T
regulatory cells (Tregs), B cells, NK cells, NK-T cells, cDC,
pDC, MDSC) and the various markers used to identify the
“refined” subsets within each classic cell type, along with a
brief description of what is generally known about each
subset. Figure 1 shows an example of the flow cytometry
gating strategy employed in these studies using PBMC
from a cancer patient following nine cycles of avelumab to
identify the 123 immune cell subsets.
As the ability to correctly detect and enumerate PD-
L1 positive immune cells is fundamental for this study,
experiments were performed to ensure that PD-L1 posi-
tive cells could be correctly identified in the staining and
gating schema. PBMC from a healthy donor were stained
with PD-L1 alone, as well as with multiparametric stains
of PD-L1 in each of the five staining panels, and assessed
for PD-L1 surface expression, with fluorescence minus
one (FMO) controls used for gating. Total PBMC, as well
as those in the lymphocyte-monocyte region and non-
lymphocyte-monocyte region, expressed a similar fre-
quency of PD-L1 when cells were stained with PD-L1
alone, or PD-L1 in the multiparametric stains, demonstrat-
ing that this antibody is compatible in combination with
the other antibodies that are needed to identify the various
immune cell subsets (Additional file 2: Figure S2). In
addition, experiments were undertaken to ensure that the
PD-L1 clone used to detect surface PD-L1 in the various
immune cell subsets was not blocked by the potential
binding of avelumab to the immune cells. PBMC were
pre-incubated for 30 min with avelumab or an IgG1 con-
trol (0.2, 2, and 20 μg/mL), and then stained with the anti-
body panels to detect PD-L1 expression in the various
immune cell subsets. As seen in Additional file 2: Table S3,
PD-L1 was detectable, and measured at a very similar fre-
quency within immune cell subsets (data shown of CD4,
CD8, cDC and B cells, both as a percentage of parent and
percentage of total PBMC), regardless of whether the
PBMC were pre-incubated with the IgG1 isotype control
or avelumab. These results demonstrate that the PD-L1
clone (MIH-1) used in the present study to assess surfaceexpression of PD-L1 does not compete for binding with
avelumab in PBMC, and can thus be used to measure PD-
L1 expression in patients treated with avelumab.
PBMC from 28 patients in the Phase I trial were first
analyzed at baseline (prior to receiving avelumab) for the
surface expression of PD-L1 on each of the nine classic
cell types and 16 refined subsets. Table 2 shows the me-
dian percentage of each cell type expressing PD-L1, both
as a percentage of total PBMC as well as a percentage of
the parental cell type. Representative flow cytometry
plots of PD-L1 within CD4+ T cells, B cells, cDC and
MDSC, as well as FMO control used for gating, are
shown in Fig. 2a. Figure 2b shows the range at baseline
of expression of PD-L1 on the nine classic cell types as a
Fig. 2 Baseline (pre-treatment) expression of PD-L1 as a percentage of parental classic subset. a Representative flow cytometry plots of
PD-L1 expression in CD4+ T cells, B cells, cDC, and MDSC. b In 28 patients prior to avelumab therapy, expression of PD-L1 was measured
by flow cytometry for nine classic subsets as a percentage of total PBMC, with graphs displaying median and interquartile range
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shows the range of expression at baseline of PD-L1 of a
given cell type as a percentage of total PBMC. For ex-
ample, while only 0.1 to 3% of PBMC are PD-L1+ MDSC
(Fig. 3, lower right panel), 5 to 35% of MDSC express
PD-L1 (Fig. 2b, lower right panel). Also shown is the
variation in PD-L1 expression amongst the parental im-
mune cell types with the highest level of expression of
PD-L1 seen on B cells and MDSC (Fig. 3).
Changes in the levels of PD-L1 expressing cells in
PBMC were then evaluated after patients received one,
three and nine cycles of avelumab every 2 weeks. Using
the criteria of a Holm adjusted p-value as detailed in the
Methods section, there were no significant changes in
any of the nine classic immune cell types, or in the PD-
L1 expressing classic cell subsets following one, three or
nine cycles of avelumab. No differences were seen in
results after one or three cycles of avelumab; thus onlyFig. 3 Baseline (pre-treatment) expression of PD-L1 as a percentage of tota
was measured by flow cytometry for nine classic subsets as a percentage othe results after one cycle and nine cycles are shown;
data following three cycles of avelumab is available in
Additional file 1: Table S4. Table 3A shows the percent-
age of patients who had an increase of more than 25%, a
minimal change (change less than the 25% cutoff ), or a
decrease of more than 25% in the nine classic cell types
after one or nine cycles of avelumab. There were some
trends in classic cell types expressing PD-L1 after nine
bi-weekly cycles of avelumab (Table 3B); there was an
increase in some patients of PD-L1+ pDC and PD-L1+
MDSC. None of these trends, however, met statistical
significance using the Holm adjusted criteria. We also
evaluated additional refined subsets expressing PD-L1
for changes after one, three and nine cycles of avelumab.
Only one PD-L1+ refined subset met statistical signifi-
cance using the Holm adjusted criteria, and this change
(an increase) only occurred following nine cycles of ave-
lumab (PD-L1+ lineage negative MDSC, Holm adjustedl PBMC. In 28 patients prior to avelumab therapy, expression of PD-L1
f total PBMC, with graphs displaying median and interquartile range
Table 3 Effect of avelumab on classic and PD-L1+ classic immune cell subsets
Pre vs 1 cycle Pre vs 9 cycles
Subset Increase Minimal change Decrease P-value Increase Minimal change Decrease P-value
A. Classic subsets
CD4 0 (0%) 18 (95%) 1 (5%) 0.0230 (↑^, 0.2070) 0 (0%) 12 (75%) 4 (25%) 0.0063 (↓^, 0.0567)
CD8 1 (5%) 16 (84%) 2 (11%) 0.1447 (=) 3 (19%) 11 (68%) 2 (13%) 0.9799 (=)
Tregs 7 (37%) 10 (53%) 2 (10%) 0.2253 (=) 2 (12%) 7 (44%) 7 (44%) 0.0934 (=)
NK 5 (26%) 10 (53%) 4 (21%) 0.8288 (=) 0 (0%) 9 (56%) 7 (44%) 0.0182 (↓^, 0.1456)
NK-T 2 (11%) 15 (78%) 2 (11%) 0.2413 (=) 1 (6%) 12 (75%) 3 (19%) 0.1046 (=)
B cells 5 (26%) 12 (63%) 2 (11%) 0.7381 (=) 6 (38%) 5 (31%) 5 (31%) 0.8209 (=)
cDC 3 (16%) 15 (79%) 1 (5%) 0.3955 (=) 6 (37%) 7 (44%) 3 (19%) 0.7436 (=)
pDC 6 (32%) 8 (42%) 5 (26%) 0.4900 (=) 6 (38%) 9 (56%) 1 (6%) 0.0833 (=)
MDSC 8 (42%) 8 (42%) 3 (16%) 0.1232 (=) 8 (50%) 7 (44%) 1 (6%) 0.0833 (=)
B. PD-L1+ classic subsets
PD-L1+ CD4 5 (26%) 9 (48%) 5 (26%) 0.9843 (=) 3 (19%) 9 (56%) 4 (25%) 0.9999 (=)
PD-L1+ CD8 4 (21%) 9 (47%) 6 (32%) 0.1688 (=) 4 (25%) 9 (56%) 3 (19%) 0.9999 (=)
PD-L1+ Treg n/a n/a n/a n/a n/a n/a n/a n/a
PD-L1+ NK 5 (26%) 6 (32%) 8 (42%) 0.4180 (=) 7 (44%) 7 (44%) 2 (12%) 0.1046 (=)
PD-L1+ NK-T 5 (26%) 8 (42%) 6 (32%) 0.4900 (=) 6 (38%) 6 (38%) 4 (24%) 0.1439 (=)
PD-L1+ B cells 9 (47%) 6 (32%) 4 (21%) 0.6507 (=) 6 (37%) 7 (44%) 3 (19%) 0.5282 (=)
PD-L1+cDC 5 (26%) 8 (42%) 6 (32%) 0.3736 (=) 2 (13%) 4 (25%) 10 (62%) 0.0386 (↓*, 0.0772)
PD-L1+ pDC 3 (16%) 2 (10%) 14 (74%) 0.0258 (↓*, 0.0774) 10 (63%) 1 (6%) 5 (31%) 0.0443 (↑, 0.1005)
PD-L1+ MDSC 8 (42%) 6 (32%) 5 (26%) 0.6507 (=) 10 (63%) 4 (25%) 2 (12%) 0.0131 (↑, 0.1703)
Classic subsets (A) and PD-L1+ classic subsets (B) were examined pre-therapy and post-1 cycle (n = 19) and 9 cycles (n = 16) of avelumab. Results are displayed as
the number of patients (percentage of total patients) with an increase of more than 25%, minimal change of less than 25%, and a decrease of more than 25%
compared to pre-therapy. Unadjusted p-values (= indicates no change; arrows indicate direction of change compared to pre-therapy; and Holm adjusted p-value
is listed for subsets with significant unadjusted p-value) were calculated using the Wilcoxon matched-pairs signed rank test. n/a = not applicable as frequency of
subset <0.01% PBMC; ^ = majority of patients with minimal change; * = difference in medians pre- vs post-therapy < 0.01
cDC conventional dendritic cells, MDSC myeloid derived suppressor cell, NK natural killer, pDC plasmacytoid DC, PBMC peripheral blood mononuclear cell, Tregs
regulatory T cells
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an additional 89 refined immune cell subsets relating to
maturation and function. Table 4 shows the subsets that
met the criteria for a trend (unadjusted p-value) at any
dose; however, none met statistical significance for a
change (Holm adjusted p-value). Representative graphs
show degree of change in subsets meeting the trend cri-
teria in patients receiving one cycle of 1, 3, 10, or 20 mg/
kg of avelumab (Fig. 4). Trends in change from baseline
were seen in more cell types after nine cycles of avelumab
vs. one or three cycles (Table 4). Since these were patients
with metastatic disease, these changes could be due to dis-
ease progression; however, none were statistically signifi-
cant using the Holm adjusted p-value (Table 4).
We also conducted additional studies using autologous
PBMC from healthy donors as targets to determine if
avelumab would mediate ADCC of PBMC using NK
cells as effectors. We have previously shown [3] that ave-
lumab can mediate ADCC against the human lung can-
cer line H441; thus it was used as a positive control. As
seen in Fig. 5a, 100% of H441 tumor cells express PD-L1, the target of avelumab. Using NK cells isolated from
five healthy donors as effector cells, avelumab mediated
appreciable ADCC of H441 target cells at multiple ef-
fector to target ratios compared to the isotype control
MAb (which denotes endogenous NK lysis) (Fig. 5b).
Using the same healthy donor NK cells with avelumab,
no lysis of autologous PBMC was seen; however, due to
the sensitivity of the assay, one cannot rule out the lysis
of a minor subpopulation of cells that express PD-L1.
Studies were performed to address the concern of the
ADCC assay sensitivity, as well as to investigate the abil-
ity of cancer patient NK cells to mediate ADCC of PD-
L1 expressing targets. NK cells were isolated from a
metastatic cancer patient with NSCLC, and tested for
their ability to induce avelumab mediated ADCC against
autologous PBMC that were sorted to enrich for PD-L1
positive and negative subsets. As seen in Fig. 6a, com-
pared to total PBMC, in which 17% of cells were positive
for PD-L1, expression of PD-L1 was negligible (<1%
positive) in the PD-L1 negative sorted fraction and
markedly enriched in the PD-L1 positive sorted fraction
Table 4 Effect of avelumab on 89 refined immune cell subsets
Post Subset Increase Minimal change Decrease Unadjusted P-value Direction Holm adjusted P-value
1 cycle PD-1+ ICOS+ CD4 12 (63%) 5 (26%) 2 (11%) 0.0181 ↑ 0.5611
PD-1+ Tregs 12 (63%) 5 (26%) 2 (11%) 0.0141 ↑ 0.0705
Functional intermediate NK 10 (53%) 6 (31%) 3 (16%) 0.0401 ↑ 0.5213
3 cycles Functional intermediate NK 1 (7%) 4 (29%) 9 (64%) 0.0295 ↓ 0.4130
9 cycles CTLA-4+ EM CD8 9 (56%) 6 (38%) 1 (6%) 0.0250 ↑ 0.6250
Functional intermediate NK 2 (12%) 4 (25%) 10 (63%) 0.0386 ↓ 0.5018
PD-1+ pDC 10 (63%) 2 (12%) 4 (25%) 0.0335 ↑ 0.1005
CD16+ MDSC 9 (56%) 5 (31%) 2 (13%) 0.0092 ↑ 0.1288
gMDSC 11 (69%) 2 (12%) 3 (19%) 0.0131 ↑ 0.1703
CD16+ gMDSC 10 (62%) 3 (19%) 3 (19%) 0.0155 ↑ 0.1705
PD-1+ lin neg MDSC 10 (62%) 4 (25%) 2 (13%) 0.0182 ↑ 0.1820
The frequency of 89 refined immune cell subsets was examined pre-therapy and post-1 cycle (n=19), 3 cycles (n=14), and 9 cycles (n=16) of avelumab. Table displays
subsets that met criteria as a potentially biologically relevant trend. Results are displayed as the number of patients (percentage of total patients) with an increase of
more than 25%, minimal change of less than 25%, and a decrease of more than 25% compared to pre-therapy. Unadjusted p-values (direction of change compared to
pre-therapy) were calculated using the Wilcoxon matched-pairs signed rank test, and Holm adjustment was made for the number of subsets within the classic subsets
with a frequency above 0.01% of PBMC
EM effector memory, gMDSC granulocytic MDSC, ICOS inducible T cell co-stimulator, lin neg MDSC lineage negative MDSC, MDSC myeloid derived suppressor cell,
NK natural killer, pDC plasmacytoid DC, PD-1 programmed cell death protein 1, Tregs regulatory T cells
Fig. 4 Immune cell subsets of a potentially biologic relevance following different doses of avelumab. Graphs display frequency as a percentage of
PBMC for patients treated with 1 or 3 mg/kg (left panels, triangle), 10 mg/kg (middle panels, circle), and 20 mg/kg (right panels, square) of avelumab
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Fig. 5 ADCC assay using PBMC from healthy donors or H441 human lung tumor cells as targets. a PD-L1 expression in H441 cells. b NK cells were
purified from PBMC from five healthy donors using negative magnetic selection. In vitro ADCC assays were performed at effector:target ratios of
25:1, 12.5:1, and 6.25:1, using an IgG1 isotype control antibody (gray bars, 1 ng/mL) or avelumab (black bars, 1 ng/mL). Results are displayed as
mean + SEM of triplicate wells
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of cells expressed PD-L1 (H460) and 100% of cells
expressed PD-L1 (H441) were used as positive controls
(Fig. 6b). Here, using NK cells from a cancer patient as
effector cells, avelumab mediated appreciable ADCC of
both H460 and H441 target cells at an effector:target ratio
of 25:1 compared to the isotype control MAb; however,
using the same patient's NK cells with avelumab, no lysis
of either total, PD-L1 negative, or PD-L1 positive enriched
PBMC was detected (Fig. 6c). Similar results were ob-
served with NK cells from two additional cancer patients
(data not shown). Notably, the expression of PD-L1 in the
positively sorted fraction of cancer patient PBMC (both %
and MFI) was similar to that of the H460 cells, but less
than that seen in the H441 cells (Fig. 6d).
As NK CD16 polymorphism has been shown [20] to
contribute to the variability of the level of ADCC medi-
ated by NK cells, the genotype of the NK CD16 used as
effectors was examined for the healthy donors in these
experiments. Four of the five healthy donors used in the
in vitro ADCC assay had the V/F genotype, while one
had the F/F genotype; the genotype of the cancerpatients used in vitro ADCC assays is unknown. The ge-
notypes of 25 of the 28 patients treated with avelumab
that were assessed by flow cytometry were determined;
12 patients had the F/F genotype, 11 had the V/F geno-
type, and 2 had the V/V genotype.
We have previously shown [21, 22] that sCD27 in
serum is a marker of T-cell activation and sCD40L in
serum is an indicator of immune suppression. Preliminary
data has also suggested that increases in the ratio of
sCD27:sCD40L correlate with improved patient outcome
in some immunotherapy trials. As seen in Fig. 7, there
were statistical increases in the sCD27:sCD40L ratio after
one administration and three administrations of avelumab
(p = 0.0087 and p = 0.0001, respectively).
Discussion
The limited toxicity observed in the dose escalation
Phase I trial and Phase II trials, and the results described
here on the minimal effect of avelumab on 123 immune
cell subsets of patients receiving avelumab should help
reduce concern about the use of a fully human IgG1 di-
rected against PD-L1. It should be noted that several
Fig. 6 ADCC assay using NK cells from a cancer patient with NSCLC against autologous PBMC sorted to enrich for PD-L1, or H460 or H441 human
lung tumor cells. a PD-L1 expression in total PBMC, and PBMC magnetically sorted via negative and positive selection to enrich for PD-L1 negative and
PD-L1 positive fractions, respectively. b PD-L1 expression in H460 and H441 cells. c NK cells were purified from PBMC from a cancer patient using
negative magnetic selection. In vitro ADCC assays were performed at effector:target ratio of 25:1, using an IgG1 isotype control antibody
(gray bars, 1 ng/mL) or avelumab (black bars, 1 ng/mL). Results are displayed as mean + SEM of triplicate wells. Data analyzed with unpaired T-test
comparing avelumab vs isotype control; **p < 0.01, ***p < 0.001; ns: not significant. d Comparison of PD-L1 expression (% positivity and mean
fluorescence intensity, MFI) in the PD-L1+ enriched PBMC fraction from three cancer patients compared to H460 and H441 cells
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Fig. 7 Effect of avelumab on soluble factors. Plasma levels of sCD27 and sCD40L were measured at baseline (pre-therapy) and following one
cycle (a, n = 39) and three cycles (b, n = 33) of avelumab. Graphs display the ratio of sCD27 to sCD40L. Following one and three cycles of
avelumab, there was a statistically significant increase in the ratio (p = 0.0087 and p = 0.0001, respectively, using the Wilcoxon matched-pairs
signed rank test)
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trastuzumab (Herceptin), cetuximab (Erbitux), and ritux-
imab (Rituxan), are all of the same human IgG1 isotype.
While the targets for each of these MAbs are also
expressed on some normal tissues, their clinical effect-
iveness has been shown to outweigh toxicities. The ac-
tual mode of action of trastuzumab, cetuximab, and
rituximab is generally accepted to be due to the reactiv-
ity of each MAb to its respective receptor on tumor
cells; evidence also exists, however, that some anti-
tumor activity of each of these three antibodies may be
due to ADCC. It is known that human NK cells posses-
sing the high affinity V/V CD16 allele generally have
more potent ADCC activity than NK cells possessing the
lower affinity F/F or V/F CD16 alleles. It has been shown
in some prior clinical studies that patients expressing
the V/V CD16 allele have greater clinical benefit, when
receiving trastuzumab, cetuximab or rituximab, than
those patients with the V/F or F/F allele [20, 23]. The
genotype of the CD16 allele was assessed in patients of
the current Phase I dose escalation trial of avelumab, and
the V/V genotype was rarely identified (2/25 patients). In
future randomized trials of avelumab, studies will be
carried out to determine if clinical benefit of avelumab
correlates with the V/V CD16 allele on NK cells.
An anti-PD-L1 MAb of the IgG1 isotype also enables
the potential for enhanced ADCC activity by employing
agents such as IL-15 and IL-12 immunocytokines. Re-
cent preclinical and clinical studies with recombinant
IL-15 [24, 25] and an IL-15/Ra/Fc immunocytokine [26,
27] have shown that these agents greatly enhance the
level of NK cells as well as the lytic activity of NK cells
on a per cell basis. In vitro studies have shown that IL-
12 also enhances NK-mediated ADCC employing avelu-
mab [3]. A tumor targeting IL-12 immunocytokine,designated NHS-IL-12, is currently in clinical studies
and may be of use toward this goal. The use in adoptive
transfer of allogeneic NK cells (NK-92) has previously
been shown to be safe with evidence of clinical activity;
a variant of NK-92 genetically engineered to express
both IL-2 (and consequent high levels of granzyme) and
the high affinity CD16 V/V allele has now been shown
to greatly enhance the ADCC activity of avelumab
[manuscript submitted for publication]. Since only ap-
proximately 10% of humans endogenously express the
V/V allele [28], the adoptive transfer of these CD16 high
affinity NK (haNK) cells in combination with avelumab
merits further investigation.
Analyses of the 123 immune subsets in the periphery
also have other potential applications. It has recently
been shown [29] that analyses of refined peripheral im-
mune cell subsets in patients from two randomized tri-
als, prior to the initiation of immunotherapy, were able
to predict, with statistical significance, those patients
more likely to benefit clinically. This was not the case
when classic immune cell subsets were analyzed in an
identical manner. Results from these two randomized
trials showed that the analyses of refined cell subsets did
not predict patient benefit in the arms of the trials in
which patients received chemotherapy alone or radio-
nuclide alone, but only predicted benefit in the arms of
the trials in which patients received vaccine plus chemo-
therapy or vaccine plus radionuclide. The analyses of
immune cell subsets in the periphery, prior to the initi-
ation of immunotherapy, have also been reported by sev-
eral groups to be a potential indicator of those patients
most likely to achieve clinical benefit [30, 31]. While it is
clear that analysis of biopsies for the presence of im-
mune infiltrate has been shown in some cases to be an
important predictor of clinical benefit, especially in the
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cer patients [32], the metastatic lesions of many cancer
types are not always amenable to biopsy. Moreover, it is
known that there is often an interplay between different
immune cell types. The analyses of the 123 immune cell
subsets in the periphery could add potentially valuable
information to that obtained in analyses of available bi-
opsy specimens; thus the dual analyses of specific im-
mune subsets in tumor and in the periphery may be of
optimal benefit in helping to define patient outcome. As-
sessment of soluble factors in sera or plasma that can
easily be tracked in patients over time can also provide an
overall indication of the immune environment induced
following a given therapy. In the present study, exposure
to avelumab significantly increased the ratio of sCD27/
sCD40L. Previous studies [21, 22] have found that sCD27
is a marker of T-cell activation, while sCD40L is a meas-
ure of immune suppression, and that increases and de-
creases, respectively in these measures in patient serum/
plasma, correlate with improved outcome in some im-
munotherapy trials. Future studies of avelumab in expan-
sion cohorts will assess if there is any link between clinical
efficacy and the trends of changes in soluble factors (in-
crease in the ratio of sCD27/sCD40L) and specific periph-
eral immune cell subsets.
It is understood that there are a number of limitations
in the current study. PD-L1, for example, is expressed at
a low level in many immune cell types in the periphery;
however, as seen in Fig. 2b, there are some subsets such
as dendritic cells, B cells, and MDSCs that were identi-
fied as expressing higher levels of this marker. In
addition, it has been reported that cryopreservation may
impact PD-L1 expression, reducing expression on mono-
cytes and CD8+ T cells, but not on CD4+ T cells [33].
However, because of the need to analyze clinical trial
samples in batches (pre- and all post-treatment samples
from the same patient assayed at the same time) to re-
duce other experimental variables, the present study
assessed cryopreserved material. Importantly, PBMC
samples pre- and post-treatment were isolated and cryo-
preserved in the same manner following stringent proto-
cols, and a live/dead discriminator was used to exclude
dead cells that bind non-specifically to antibody. It is
also recognized that PD-L1 expression can be temporally
influenced by therapies that induce immune activation,
and that expression of immune cells in the periphery
may likely differ from what is seen within the tumor.
Despite all of these limitations, we show that there is no
marked loss of PD-L1 expressing immune cells in the
peripheral blood of patients treated with avelumab.
Studies are planned to examine the immune effects of
avelumab within the tumor microenvironment in future
expansion cohorts of avelumab in patients with tumors
that can be biopsied, where PD-L1 may be more broadlyexpressed and upregulated on immune cells by the im-
mune potentiating properties of avelumab.
NK cells are known to express numerous Ig-like re-
ceptors and C-type lectin receptors that deliver a finely
tuned balance of activating and inhibitory signals that
can influence their ability to discriminate between self/
healthy cells from transformed/pathogen infected cells
[34]. We demonstrate in the present study that NK
cells isolated from metastatic NSCLC patients induce
avelumab mediated ADCC of human lung tumor cell
lines but not of autologous PBMC, including those that
have been sorted to enrich for expression of PD-L1, the
target of avelumab. This is in concordance with the
finding of Voskens et al. [35], that ex vivo expanded hu-
man NK cells expressing high levels of activating recep-
tors can mediate cytotoxicity of cancer cell lines by
direct recognition and ADCC, but do not lyse autolo-
gous PBMC. In that study it was postulated that the in-
hibitory ligands expressed on normal PBMC may
predominate over activating signals, in order to be able
to control the NK-mediated cytolytic activity against
non-malignant cells.Conclusions
In conclusion, our data show a lack of any significant
effect on 123 peripheral immune cell subsets, includ-
ing those that express PD-L1, following treatment of
cancer patients with multiple cycles of avelumab. We
also demonstrate in controlled in vitro experiments
that avelumab can mediate ADCC of PD-L1 express-
ing tumor cells, but not against PD-L1 expressing im-
mune cells. These findings complement the limited
toxicity observed in the dose escalation Phase I and
Phase II trials of avelumab, and should help to reduce
concern about the use of a fully human IgG1 MAb
directed against PD-L1. This study also supports the
rationale to further exploit the potential ADCC mech-
anism of action of avelumab against tumor cells to
potentially enhance clinical activity.Additional files
Additional file 1: Table S1. Antibodies used for 5 panel stain to identify
123 peripheral immune cell subsets. Panel 1: PD-1 signaling; Panel 2: CD4+ T
cells, CD8+ T cells, B cells; Panel 3: Tregs; Panel 4: NK, NK-T, cDC, pDC; Panel 5:
MDSC. Table S2. Peripheral immune cell subsets analyzed by flow cytometry.
Analysis of 123 subsets using 30 unique markers. Table S3. PD-L1 clone MIH-
1 used to detect surface expression of PD-L1 in immune cell subsets does
not compete for binding with avelumab. Table S4. Effect of three cycles of
avelumab on classic and PD-L1+ classic immune cell subsets. Classic and PD-
L1+ classic subsets were examined pre-therapy and post-three cycles (n = 14)
of avelumab. Table S5. Effect of avelumab on PD-L1+ refined immune cell
subsets. PD-L1+ refined subsets were examined pre-therapy and post-one
cycle (n = 19), three cycles (n = 14), and nine cycles (n = 16) of avelumab.
(PDF 464 kb)
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detection of up to 11 markers per staining panel. Figure S2. PD-L1
expression in PBMC from a healthy donor stained with single and
multiparametric stains of PD-L1. (PDF 520 kb)
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